Business context and reporting period
This is Inotek Pharmaceuticals Corporation’s unaudited Form 10-Q for the quarter ended March 31, 2016—not a filing under the name Rocket Pharmaceuticals, Inc. The company was a clinical-stage ophthalmology biopharmaceutical developer with no approved products or product-sales revenue. Its lead candidate, trabodenoson, was in Phase 3 development as a glaucoma monotherapy; a trabodenoson/latanoprost fixed-dose combination was in development.
Financial results and liquidity
Amounts below are in millions of dollars unless otherwise noted.
| Metric | Q1 2016 | Q1 2015 |
|---|---|---|
| Revenue | No product-sales revenue | No product-sales revenue |
| Research and development expense | $7.615 | $1.069 |
| General and administrative expense | $2.522 | $1.980 |
| Operating loss | $10.137 | $3.049 |
| Net loss | $10.068 | $1.462 |
| Net loss per share | $0.38 | $0.21 |
| Cash used in operating activities | $8.993 | $1.993 |
- R&D growth reflected clinical-trial activity and preparation for further development; management attributed the increase primarily to higher clinical-trial costs, as well as preclinical, personnel and consulting costs. No operating margin is meaningful given the absence of product revenue.
- At March 31, 2016, cash and cash equivalents were $58.706 million and short-term investments were $43.559 million, totaling $102.265 million. Total current assets were $103.247 million and current liabilities were $4.614 million.
- Cash and cash equivalents declined $21.336 million during the quarter. Investing cash outflow of $12.343 million primarily reflected purchases of short-term investments, net of maturities.
- Total liabilities were $4.965 million. The 2020 convertible notes had been converted into stock in 2015, and other notes payable had been repaid; the filing reports no debt outstanding at quarter-end.
- Accumulated deficit was $206.091 million. The company estimated available cash and investments would fund projected operating requirements through 2017, but stated additional financing would be needed in the future.
Material changes versus the prior comparable period
- Net loss increased to $10.068 million from $1.462 million, and operating loss increased to $10.137 million from $3.049 million, primarily reflecting the ramp-up of clinical development and increased company infrastructure.
- R&D expense rose $6.546 million; management cited a $4.4 million increase in clinical-trial expense, $0.9 million in preclinical expense, $0.8 million in employee-related expense and $0.3 million in consulting expense.
- G&A expense rose $0.542 million. Increased staffing, public-company, consulting and legal costs were partly offset by lower stock-based compensation related to 2015 IPO vesting events.
- Q1 2015 included interest expense, debt-extinguishment losses and noncash gains from changes in derivative and warrant fair values. These items were absent in Q1 2016; Q1 2016 instead recorded $0.069 million of interest income.
- Weighted-average shares increased to 26.4 million from 7.7 million, reflecting the 2015 IPO and subsequent capital transactions.
Outlook, risks and unusual items
- Management expected top-line data from the first pivotal Phase 3 trabodenoson monotherapy trial by late 2016 and anticipated beginning Phase 2 testing of the fixed-dose combination in the second half of 2016. These are forward-looking expectations, not reported outcomes.
- Management expected operating losses and R&D expense to continue increasing, and said additional trials, commercialization preparation and public-company costs would require substantial funding. The April 2016 Form S-3 registration statement covered up to $200 million of securities; a sales-agreement prospectus allowed up to $50 million of common stock and was included within that $200 million amount.
- Key risks include clinical-trial efficacy, safety and enrollment; regulatory delay or failure; the ability to formulate and manufacture the fixed-dose combination; reliance on third-party manufacturers and a single active-ingredient supplier; financing availability and potential dilution; competition, reimbursement and market adoption; and intellectual-property protection.
- The filing notes potential cardiovascular effects associated with adenosine-like drugs, while stating data to date showed no systemic cardiovascular effects from trabodenoson when dosed in the eye. Further trials remained necessary.
- The company reported $2.8 million of operating-lease commitments, including additional office space expected to be occupied in July 2016. It reported no current legal proceedings and said disclosure controls were effective at a reasonable-assurance level, with no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing is for Inotek Pharmaceuticals Corporation, despite the request metadata naming Rocket Pharmaceuticals, Inc.
- Check subsequent clinical-trial disclosures against the stated late-2016 data target and planned second-half 2016 fixed-dose-combination trial.
- Assess whether the estimated runway through 2017 remains supportable given the reported operating cash use and planned development spending.
- Review the April 2016 shelf and sales-agreement registration documents for actual securities issued, proceeds raised and resulting dilution.
- Verify clinical safety and efficacy, manufacturing readiness, supplier continuity, and any changes to regulatory or financing assumptions.